Report cover image

Global Ipilimumab Injection Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 199 Pages
SKU # APRC20278852

Description

Summary

According to APO Research, the global Ipilimumab Injection market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Ipilimumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Ipilimumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Ipilimumab Injection market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Ipilimumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Ipilimumab Injection market include Bristol Myers Squibb. etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Ipilimumab Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Ipilimumab Injection, also provides the sales of main regions and countries. Of the upcoming market potential for Ipilimumab Injection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ipilimumab Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Ipilimumab Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Ipilimumab Injection sales, projected growth trends, production technology, application and end-user industry.


Ipilimumab Injection Segment by Company


Bristol Myers Squibb

Ipilimumab Injection Segment by Type


50mg per Vial

200mg per Vial

Ipilimumab Injection Segment by Application


Malignant Thymic Mesothelioma

Non-small Cell Lung Cancer

Hepatocellular Carcinoma

Melanoma

Colorectal Cancer

Renal Cell Carcinoma

Other

Ipilimumab Injection Segment by Region


North America


United States

Canada

Mexico

Europe


Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific


China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America


Brazil

Argentina

Chile

Middle East & Africa


Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Ipilimumab Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Ipilimumab Injection market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Ipilimumab Injection significant trends, drivers, influence factors in global and regions.
6. To analyze Ipilimumab Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ipilimumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ipilimumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ipilimumab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ipilimumab Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ipilimumab Injection industry.
Chapter 3: Detailed analysis of Ipilimumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Ipilimumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Ipilimumab Injection in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Ipilimumab Injection Sales Value (2020-2031)
1.2.2 Global Ipilimumab Injection Sales Volume (2020-2031)
1.2.3 Global Ipilimumab Injection Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Ipilimumab Injection Market Dynamics
2.1 Ipilimumab Injection Industry Trends
2.2 Ipilimumab Injection Industry Drivers
2.3 Ipilimumab Injection Industry Opportunities and Challenges
2.4 Ipilimumab Injection Industry Restraints
3 Ipilimumab Injection Market by Company
3.1 Global Ipilimumab Injection Company Revenue Ranking in 2024
3.2 Global Ipilimumab Injection Revenue by Company (2020-2025)
3.3 Global Ipilimumab Injection Sales Volume by Company (2020-2025)
3.4 Global Ipilimumab Injection Average Price by Company (2020-2025)
3.5 Global Ipilimumab Injection Company Ranking (2023-2025)
3.6 Global Ipilimumab Injection Company Manufacturing Base and Headquarters
3.7 Global Ipilimumab Injection Company Product Type and Application
3.8 Global Ipilimumab Injection Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Ipilimumab Injection Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Ipilimumab Injection Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Ipilimumab Injection Market by Type
4.1 Ipilimumab Injection Type Introduction
4.1.1 50mg per Vial
4.1.2 200mg per Vial
4.2 Global Ipilimumab Injection Sales Volume by Type
4.2.1 Global Ipilimumab Injection Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Ipilimumab Injection Sales Volume by Type (2020-2031)
4.2.3 Global Ipilimumab Injection Sales Volume Share by Type (2020-2031)
4.3 Global Ipilimumab Injection Sales Value by Type
4.3.1 Global Ipilimumab Injection Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Ipilimumab Injection Sales Value by Type (2020-2031)
4.3.3 Global Ipilimumab Injection Sales Value Share by Type (2020-2031)
5 Ipilimumab Injection Market by Application
5.1 Ipilimumab Injection Application Introduction
5.1.1 Malignant Thymic Mesothelioma
5.1.2 Non-small Cell Lung Cancer
5.1.3 Hepatocellular Carcinoma
5.1.4 Melanoma
5.1.5 Colorectal Cancer
5.1.6 Renal Cell Carcinoma
5.1.7 Other
5.2 Global Ipilimumab Injection Sales Volume by Application
5.2.1 Global Ipilimumab Injection Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Ipilimumab Injection Sales Volume by Application (2020-2031)
5.2.3 Global Ipilimumab Injection Sales Volume Share by Application (2020-2031)
5.3 Global Ipilimumab Injection Sales Value by Application
5.3.1 Global Ipilimumab Injection Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Ipilimumab Injection Sales Value by Application (2020-2031)
5.3.3 Global Ipilimumab Injection Sales Value Share by Application (2020-2031)
6 Ipilimumab Injection Regional Sales and Value Analysis
6.1 Global Ipilimumab Injection Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Ipilimumab Injection Sales by Region (2020-2031)
6.2.1 Global Ipilimumab Injection Sales by Region: 2020-2025
6.2.2 Global Ipilimumab Injection Sales by Region (2026-2031)
6.3 Global Ipilimumab Injection Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Ipilimumab Injection Sales Value by Region (2020-2031)
6.4.1 Global Ipilimumab Injection Sales Value by Region: 2020-2025
6.4.2 Global Ipilimumab Injection Sales Value by Region (2026-2031)
6.5 Global Ipilimumab Injection Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Ipilimumab Injection Sales Value (2020-2031)
6.6.2 North America Ipilimumab Injection Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Ipilimumab Injection Sales Value (2020-2031)
6.7.2 Europe Ipilimumab Injection Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Ipilimumab Injection Sales Value (2020-2031)
6.8.2 Asia-Pacific Ipilimumab Injection Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Ipilimumab Injection Sales Value (2020-2031)
6.9.2 South America Ipilimumab Injection Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Ipilimumab Injection Sales Value (2020-2031)
6.10.2 Middle East & Africa Ipilimumab Injection Sales Value Share by Country, 2024 VS 2031
7 Ipilimumab Injection Country-level Sales and Value Analysis
7.1 Global Ipilimumab Injection Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Ipilimumab Injection Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Ipilimumab Injection Sales by Country (2020-2031)
7.3.1 Global Ipilimumab Injection Sales by Country (2020-2025)
7.3.2 Global Ipilimumab Injection Sales by Country (2026-2031)
7.4 Global Ipilimumab Injection Sales Value by Country (2020-2031)
7.4.1 Global Ipilimumab Injection Sales Value by Country (2020-2025)
7.4.2 Global Ipilimumab Injection Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.5.2 USA Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.6.2 Canada Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.8.2 Germany Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.9.2 France Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.9.3 France Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.11.2 Italy Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.12.2 Spain Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.13.2 Russia Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.16.2 China Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.16.3 China Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.17.2 Japan Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.19.2 India Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.19.3 India Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.20.2 Australia Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.24.2 Chile Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.26.2 Peru Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.28.2 Israel Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.29.2 UAE Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.31.2 Iran Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Ipilimumab Injection Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Ipilimumab Injection Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Ipilimumab Injection Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Bristol Myers Squibb
8.1.1 Bristol Myers Squibb Comapny Information
8.1.2 Bristol Myers Squibb Business Overview
8.1.3 Bristol Myers Squibb Ipilimumab Injection Sales, Value and Gross Margin (2020-2025)
8.1.4 Bristol Myers Squibb Ipilimumab Injection Product Portfolio
8.1.5 Bristol Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Ipilimumab Injection Value Chain Analysis
9.1.1 Ipilimumab Injection Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Ipilimumab Injection Sales Mode & Process
9.2 Ipilimumab Injection Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Ipilimumab Injection Distributors
9.2.3 Ipilimumab Injection Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.